550 related articles for article (PubMed ID: 27960557)
1. The biologics of ulcerative colitis.
Macaluso FS; Renna S; Orlando A; Cottone M
Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics].
Bae JH; Yang DH
Korean J Gastroenterol; 2018 Apr; 71(4):192-195. PubMed ID: 29684967
[TBL] [Abstract][Full Text] [Related]
3. Special considerations for biologic medications in pediatric ulcerative colitis.
Jerger L; Hyams JS
Expert Opin Biol Ther; 2020 Apr; 20(4):429-435. PubMed ID: 31652087
[No Abstract] [Full Text] [Related]
4. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
Moćko P; Kawalec P; Pilc A
Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
[TBL] [Abstract][Full Text] [Related]
5. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
6. Biologic Therapy for Ulcerative Colitis.
Bhattacharya A; Osterman MT
Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
8. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
9. [Golimumab Therapy in Ulcerative Colitis].
Moon W
Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
[TBL] [Abstract][Full Text] [Related]
11. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
[No Abstract] [Full Text] [Related]
12. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
13. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
14. Review of Biosimilars of Adalimumab.
Kaushik VV
J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
[TBL] [Abstract][Full Text] [Related]
15. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study.
Barberio B; Zingone F; Frazzoni L; D'Incà R; Maccarone MC; Ghisa M; Massimi D; Lorenzon G; Savarino EV
Dig Dis; 2021; 39(1):16-24. PubMed ID: 32450562
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
18. [Biological agents in ulcerative colitis. When to prescribe].
Barreiro-de Acosta M
Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():36-42. PubMed ID: 25443225
[TBL] [Abstract][Full Text] [Related]
19. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
20. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]